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Abstract
Unbiased, high-throughput screening has proven invaluable for dissecting complex biological processes. Application of this
general approach to synaptic function would have a major impact on neuroscience research and drug discovery. However,
existing techniques for studying synaptic physiology are labor intensive and low-throughput. Here, we describe a new high-
throughput technology for performing assays of synaptic function in primary neurons cultured in microtiter plates. We
show that this system can perform 96 synaptic vesicle cycling assays in parallel with high sensitivity, precision, uniformity,
and reproducibility and can detect modulators of presynaptic function. By screening libraries of pharmacologically defined
compounds on rat forebrain cultures, we have used this system to identify novel effects of compounds on specific aspects
of presynaptic function. As a system for unbiased compound as well as genomic screening, this technology has significant
applications for basic neuroscience research and for the discovery of novel, mechanism-based treatments for central
nervous system disorders.
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Introduction
The application of unbiased, high-throughput screening ap-
proaches has had a major impact on basic research and drug
discovery. For example, forward genetic screens in yeast and flies
have yielded fundamental insights into a variety of complex
biological processes [1,2], microarray-based screens have provided
a comprehensive means to examine regulation of gene expression
[3], and small molecule library screens have been critical for
identifying chemical modulators of biological processes for drug
discovery applications [4]. Despite the extensive body of research
focused on synaptic mechanisms in mammalian neurons, there are
no screening tools capable of performing dynamic measurements
of synaptic activity in a high-throughput format. Such tools would
enable the performance of genetic and pharmacological screens to
comprehensively examine the molecular biology of the synapse
and to identify novel modulators of synaptic function. Moreover,
since altered synaptic function has been associated with a number
of psychiatric and neurological disorders [5,6,7,8,9,10,11,
12,13,14], the identification of novel proteins or compounds that
modulate or restore aberrant synaptic function involved with
disease pathogenesis is an attractive approach for the discovery of
new mechanism-based therapies.
More specifically, an alteration of synaptic vesicle cycling has
been implicated in a variety of disorders, including schizophrenia,
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and
epilepsy [5,6,7,8,9,10,11,12,13,14]. A fundamental component of
synaptic transmission, synaptic vesicle cycling is a complex, multi-
stage process that includes the steps of vesicle exocytosis,
endocytosis, reinsertion into the recycling pool, mobilization to
the active site, and priming for a subsequent round of exocytosis
[15]. In recent years, powerful methods utilizing fluorescent
reporters have emerged for monitoring presynaptic function in
living neurons [16]. These assays are typically performed on a
fluorescence microscope to image the effects of physiologically
relevant patterns of action potentials, elicited by an integrated field
stimulation system, on reporters of presynaptic activity [17].
However, since these methods are time and labor intensive, they
are not amenable to unbiased screening applications.
The translation of presynaptic assays into a high-throughput
screening system is technically challenging largely due to a
requirement for long-term kinetic measurements (.5 min/well)
[17]. To achieve an acceptable throughput, a presynaptic
screening system must perform assays in all wells of a 96-well
plate in parallel. This need for parallelization imposes significant
technical demands on the imaging and stimulation components of
the technology. For example, high-content imaging systems have
single-synapse resolution and sufficient optical sensitivity, but they
are limited to measuring one well at a time [18]. In contrast, plate
readers capable of performing 96 parallel kinetic fluorescence
measurements have significantly reduced optical sensitivity.
Therefore, a presynaptic screening technology requires a parallel
imaging system with excellent optical sensitivity and a reporter
system that yields high signal density and signal-to-background
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tion of an electrode array that can deliver field potentials
simultaneously to neurons in all wells of 96-well plates such that
all neurons are exposed to uniform current densities.
Here, we report the development of the MANTRA
TM (Multi-
well Automated NeuroTRansmission Assay) system: a high-
throughput screening technology for performing assays of the
synaptic vesicle cycle in primary neurons. We demonstrate that
this system can perform 96 parallel synaptic vesicle cycle assays,
meets the critical technical specifications necessary to carry out
unbiased, functional screening of presynaptic neuronal function,
and is capable of rapidly identifying novel effects of test agents on
synaptic vesicle cycling. Through its current application and its
capacity to be extended to additional synaptic processes, this
technology has tremendous potential for broadening our under-
standing of synaptic function and, ultimately, developing new
classes of mechanism-based treatments for the many diseases
associated with synaptic dysfunction.
Results
MANTRA system development
A high throughput screening technology for monitoring
synaptic vesicle cycling requires four technology components: a
reporter system, an imaging system, a field stimulation system, and
a data analysis system. We initiated technology development by
evaluating potential solutions for these components.
We chose a pHluorin-based protein as the reporter technology
because it is genetically encoded, enabling homogeneous assays
[19], can report both vesicle exocytosis and endocytosis [20], and
can report repeated rounds of vesicle cycling [20]. This reporter
system is based on the fusion of a pH-sensitive GFP variant,
pHluorin, to the lumenal domain of a transmembrane synaptic
vesicle protein (Figure 1A). At the internal pH of a resting vesicle,
the pHluorin fluorescence is quenched. When action potentials are
elicited in neurons expressing the reporter, vesicles exocytose,
exposing the pHluorin to the neutral pH of the synaptic cleft
causing an increase in its fluorescence. Upon endocytosis and
reacidification of the vesicles, fluorescence is again quenched. Due
to its reported excellent signal-to-background properties, we opted
for a synaptophysin-pHluorin fusion construct (sypHy) in which
pHluorin is inserted into the second intralumenal loop of
synaptophysin [21].
To maximize the number of neurons expressing the reporter,
we used an adeno-associated virus (AAV) delivery system that
yields a high infection efficiency with minimal cytotoxicity [22].
To eliminate non-neuronal expression, we utilized the human
synapsin promoter [23] to drive reporter expression. Immunohis-
tochemistry performed on neurons infected with this virus (hSyn-
sypHy-AAV) demonstrated that sypHy is expressed in a punctate
pattern that colocalizes with synaptotagmin I, indicating that it is
targeted to presynaptic terminals (Figure 1B). Colocalization
analysis showed that most terminals contained detectable sypHy
levels (mean 6 SEM: 8063% synapses; n=3 cultures). Using
single-channel, high resolution microscopy [17], we verified that
this reporter system is capable of quantifying the synaptic vesicle
cycle in primary neurons (Figure 1C,D).
Since synaptic vesicle cycling assays are of long duration,
screening must be performed in 96 wells in parallel to achieve an
acceptable throughput. In addition, due to the lack of amplifica-
tion of the reporter signal, the instrument must have highly
sensitive optics. For the imaging component of the MANTRA
system, we selected the plate::vision plate reader (Perkin Elmer)
based on its parallel, high sensitivity imaging capacity. The
plate::vision measures fluorescence in a 500 mm wide segment of
each of 96 wells simultaneously and with high sensitivity by
employing a unique 96-minilens array and an intensified charge-
coupled device (CCD) camera [24]. Critically, assay plates in this
instrument are readily accessible during imaging, permitting
integration of a stimulation system.
Delivering uniform electrical stimuli to neuronal cultures in 96-
well plates is a major technical challenge. To achieve acceptable
assay variability, field stimuli must be spatially uniform across the
neurons within each well of the entire plate, which requires
carefully shaped and precisely positioned electrodes. Shape and
positioning must match precisely from well to well despite
considerable variability in the plate manufacturing process. For
these reasons, traditional field stimulation electrodes, such as
paired tungsten filaments or glass pipettes, are insufficient for the
task. Therefore, for the MANTRA stimulation system, we
identified and optimized an existing automated electroporation
system (CellaxessHT; Cellectricon) that solved these technical
hurdles as described below.
We constructed the MANTRA instrumentation by integrating a
plate::vision plate reader with a customized CellaxessHT system
within a temperature controlled cabinet (Figure 2A). In typical use,
a modified liquid handling unit with a robotic arm places the
electrode module into the assay plate. The electrodes each consist
of two concentric titanium tubes separated by a polytrifluoro-
chloroethylene (PTFCE) tip that serves as an electrical insulator
and the contact with the well bottom. The combination of force
exerted by the robot arm, an internal spring mechanism, and four
75 mm high feet on the bottom of each tip ensure that all
electrodes are at a uniform height (Figure 2B). In this position, the
outer titanium tube is submerged in assay buffer. Liquid handling
pistons draw buffer into the inner titanium tubes to create an
electrical contact between the electrodes. The plate::vision initiates
kinetic fluorescence sampling, and field stimulation pulses are then
applied by a pulse generator. Uniform electric fields are achieved
within individual wells through specific contouring of the bottom
of the PTFCE electrode tip. All stimulation, imaging, and tip
washing activities are coordinated by CellaxessHT control
software (Cellectricon).
The MANTRA system generates 96 channels of complex
waveform data. Multiple features of these waveforms yield
information about different aspects of the synaptic vesicle cycle
[25] (Figure 2C). To enable efficient analysis of these complex
data, we created a data handling system with which pulse train
information, raw fluorescence traces, extracted waveform features,
and treatment conditions are automatically loaded into a relational
database and processed, permitting visualization and further
analysis through a web-based user interface (Figure 2A). In a
typical dataset, a sypHy fluorescence response to a field
stimulation train is observed in all wells of a 96-well plate
(Figure 2D), demonstrating the capacity of the MANTRA system
to perform 96 parallel synaptic vesicle cycling assays.
MANTRA system technical performance
We undertook a series of studies to characterize the perfor-
mance of the MANTRA system in relation to the crucial
performance criteria necessary for a robust screening platform.
The ability to measure responses to multiple rounds of stimulation
is essential for monitoring presynaptic activity under a variety of
activity regimes. We exposed hSyn-sypHy-AAV infected neuronal
cultures in 96-well plates to repeated stimulus trains and observed
that sypHy responses were stable over time, changing in amplitude
by less than 2% per train on average (Figure 3A-C). Thus, the
MANTRA system can be used to repeatedly stimulate neuronal
High Throughput Screening of Synaptic Function
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bleaching or acute cytotoxicity.
To achieve uniformity of presynaptic responses, the field stimuli
applied to neurons must have a high degree of well-to-well and
plate-to-plate uniformity. We examined sypHy responses to
stimulus trains delivered at increasing voltages and observed a
sigmoid relationship between voltage and response amplitude
(Figure 3D), from which we could calculate an EV50 value for each
well (see Figure 3E legend). EV50’s were highly consistent within
and across plates (Figure 3E, F), demonstrating that the field
stimulation system consistently delivers uniform stimuli.
Analysis oftheoptical sensitivityof the MANTRAsystemshowed
that it canconsistently detectsypHy responsesto as few as 50 stimuli
within wells of a single plate and across plates (Figure 3G–I),
enabling use of a large range of stimulus regimes that place different
demands on the synaptic vesicle cycling machinery. To quantify
well-to-well and plate-to-plate variability of sypHy responses to
screening stimuli, we subjected eight plates to a protocol consisting
of three pulse trains: 5 Hz, 30 seconds; 10 Hz, 30 seconds; and
50 Hz, 15 seconds. Within-plate and between-plate summary
statistics for extracted parameters from the responses to 10 Hz
trains are shown in Table 1 and from the 5 and 50 Hz trains in
Tables S1 and S2, respectively. %CV’s across all measures were
between 10 and 18%, indicating the achievement of assay
uniformity appropriate for screening applications.
We next confirmed that the MANTRA system induces and
measures synaptic vesicle cycling in response to action potential-
mediated opening of presynaptic Ca
++ channels. First, we found
that tetrodotoxin (TTX), an inhibitor of the voltage-gated sodium
channels that carry action potentials [26], potently blocked the
fluorescence response to field stimulation (Figure 4A;
IC50=4.960.6 nM; n=3 plates), demonstrating that action
potentials are required for the sypHy signal in the MANTRA
system. Second, since synaptic vesicle fusion is triggered primarily
by Ca
++ influx through channels from the Cav2 family [27,28], we
analyzed the effects of inhibitors of these channels on the
MANTRA system. We used v-agatoxin IVA, v-conotoxin GVIA,
and SNX-482 for blockade of Cav2.1, Cav2.2, and Cav2.3,
respectively [29,30,31]. Figure 4B shows the sypHy responses
during a 30 Hz, 10 second stimulus train in the presence of these
Figure 1. SypHy delivered by AAV transduction as a reporter of presynaptic function. (A) Schematic illustrating the function of the sypHy
reporter of synaptic vesicle cycling. (B) Presynaptic localization of sypHy in neuronal cultures infected with hSyn-sypHy-AAV at 7 days in vitro (DIV)
and fixed at 22 DIV shown by colocalization of anti-GFP (green) and anti-synaptotagmin I (red) immunoreactivity. Scale bar: 10 mm. (C) Portion of a
kinetic fluorescence image series of an hSyn-sypHy-AAV infected culture prior to stimulation (1), during delivery of a 50 Hz, 10 second stimulus train
(2), 30 sec after offset of stimulus train (3), and 2 min after offset of stimulus train (4). Scale bar: 50 mm. (D) Relative fluorescence intensity of the entire
imaging field from the experiment shown in (c). Red bar indicates the stimulus.
doi:10.1371/journal.pone.0025999.g001
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reduced the sypHy response by .95% (Figure 4C; t-test:
p=10
217; n=8). At the end of the train (300 stimuli), this
treatment resulted in a .75% inhibition of the response
(Figure 4D; t-test: p=10
218; n=8). These data show that the
sypHy responses of the MANTRA system are dependent upon
action potential-mediated opening of presynaptic voltage-gated
Ca
++ channels, consistent with typical synaptic vesicle release. The
reduction in the block of fluorescence responses with increasing
stimulation is likely due to action potential broadening following
Cav2 channel inhibition [32] and an increasing amount of Ca
++
influx from other sources, such as T-type or L-type Ca
++ channels
[33,34].
Since the synaptic vesicle cycle is sensitive to temperature
fluctuations [35], a thermostat system was incorporated into the
MANTRA instrumentation. Testing under typical use conditions
showed that this system can maintain the temperature of assay
wells to within a range of 60.5uC (Figure S1). In summary, these
data demonstrate that the MANTRA system is capable of
performing 96-parallel synaptic vesicle cycling assays with high
precision, uniformity, sensitivity, and reproducibility.
MANTRA system can identify synaptic vesicle cycling
modulators
To evaluate its utility for high-throughput screening, we
examined whether the MANTRA system can detect modulators
of synaptic vesicle cycling. The phorbol ester phorbol–12-
myristate-13-acetate (PMA) has been shown to enhance synaptic
vesicle release [36]. Using our microscope-based, high-resolution
system, we found that application of PMA (1 mM) increased the
amplitude of sypHy responses to a 5 Hz, 30 sec stimulus train
(Figure 5A,B; t-test: p=0.004; n=3). We next examined the
ability of the MANTRA system to detect this compound-induced
alteration in synaptic vesicle cycling. PMA (1 mM) was added to
multiple wells of a 96-well plate, which was then subjected to the
same stimulation protocol on the MANTRA instrument. The
Figure 2. The MANTRA system. (A) Schematic depicting the MANTRA system, including the cell culture system, the reporter system, the
instrumentation, and the heatmap application of the data analysis system. (B) Schematic depicting the relative dimensions of an electrode tip and
the imaging area within a single well of a 96-well plate. (C) Representative sypHy fluorescence trace from a single well when stimulated as in (D)
showing three of the basic waveform features automatically extracted by the MANTRA system analysis software. Red bar indicates stimulus. Scale bar:
0.05 DF/F, 20 sec. (D) Representative dataset from the MANTRA system showing sypHy fluorescence responses to a 50 Hz, 15 sec stimulus train from
all wells of a 96-well plate. For each well, y-axis: 0.35 DF/F, x-axis: 180 sec.
doi:10.1371/journal.pone.0025999.g002
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from a set of three randomly selected PMA wells were significantly
greater than those of three randomly selected control wells
(Figure 5A,B; t-test: p=0.01). These results recapitulate the effects
of PMA observed using the high resolution system and confirm the
ability of the MANTRA system to measure the effects of synaptic
vesicle cycling modulators.
To demonstrate that the MANTRA system can identify
modulators of synaptic vesicle cycling in high throughput
screening mode, we screened the plate of the Library of
Pharmacologically Active Compounds (LOPAC; Sigma) that
contains PMA. Given the response variability documented in
Table 1, compounds were screened in triplicate to improve
sensitivity to modest compound effects. Each of three assay plates
contained a single copy of each compound assigned to a pseudo-
randomized well location. Neurons were stimulated with three
pulse trains that varied in frequency (5 Hz, 30 sec; 10 Hz, 30 sec;
30 Hz, 15 sec). Using a hit detection threshold set at three
standard deviations from the mean of the control well values, PMA
was detected as a hit that increased the amplitude of the response
to the 5 Hz train (Figure 5C; mean 6 SEM standard score:
5.660.56). Eleven additional hits were identified that reduced the
response to the 5 Hz train (see Dataset S1 for complete dataset).
Each of these compound effects was confirmed on a separate set of
hit confirmation plates (Figure S2).
We next generated a concentration-response curve for the
effects of PMA on the amplitude of sypHy responses to 5 Hz
stimulus trains using a single assay plate (Figure 5D). The EC50 for
Figure 3. Validation of the MANTRA system technical performance. (A) Superimposed traces from nine successive 10 Hz, 10 sec trains from
a single well. Bar indicates stimulus. Scale bars: 0.05 DF/F, 20 sec. (B) Amplitudes from all wells of a plate were calculated for the nine trains and
normalized to the first train. Shown is the mean percent change per train for each well. Amplitude change per train for all wells was 21.560.97%
(mean 6 SD). (C) Normalized amplitudes (mean 6 SD) to each train for three plates. Data were fit by linear regression (slope=20.014; r
2=0.93;
p,0.0001). Amplitude change per train across plates was 21.560.13% (mean 6 SEM; n=3). (D) Amplitudes of responses to 30 Hz, 10 sec trains
delivered at increasing voltages from a representative well. Data were fit with a sigmoid function (R
2=0.99). Inset: Individual traces. Scale bar: 0.05
DF/F, 30 sec. Bar indicates stimulus. (E) The voltage generating the 50% peak response (EV50) for each well of a plate (%CV=9.8%). (F) The EV50
(mean 6 SD) from all wells of multiple plates stimulated as in (e). (G) Amplitudes from a well stimulated with 10 sec trains of increasing frequencies.
Data were fit with a one-phase exponential curve (R
2=0.99). Inset: Individual traces. Scale bar: 0.05 DF/F, 30 sec. Bar indicates the stimulation. (H)
Signal:noise for responses to the 50 pulse train (mean 6 SD: 12.261.7) for a plate. ‘‘Signal’’ is amplitude. ‘‘Noise’’ is the standard deviation of a 10
second baseline. (I) Signal:noise (mean 6 SD) data generated from a 50 pulse train from three plates.
doi:10.1371/journal.pone.0025999.g003
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6.262.4 nM (mean 6 SEM; n=3 plates). The ability to rapidly
identify modulators of synaptic vesicle cycling and to generate a
concentration-response curve from a single plate demonstrates the
utility of the MANTRA system for screening applications.
Identification of a presynaptic modulatory mechanism
The MANTRA system generates a rich dataset regarding the
effects of compounds on multiple aspects of presynaptic function
under different activity regimes. Further analysis of the LOPAC
plate data described above revealed specific effects of compounds
on synaptic vesicle cycling induced by the different stimulation
intensities. In particular, the adenosine A1 receptor agonist N6-
phenyladenosine is the only compound on the plate that decreased
the amplitude of responses to 5 Hz stimulation (see Figure 5C)
with little or no effect on responses to 30 Hz stimulation
(Figure 6A; mean 6 SEM 30 Hz/5 Hz amplitude ratio standard
score: 3.860.86). To determine if this effect is common to
compounds with the same pharmacological activity, we screened a
plate of 71 compounds consisting of modulators of adenosine or
Table 1. MANTRA system signal uniformity analysis.
Individual Plates All Plates
Parameter 1 2 345678Mean SD %CV
Amplitude
(DF/F)
Mean 0.16 0.15 0.15 0.19 0.15 0.17 0.16 0.17 0.16 0.02 9.0
SD 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.03
%CV 13.2 11.6 12.7 10.1 15.6 17.2 15.5 15.0 13.9
Decay t
(sec)
Mean 15.5 13.3 13.0 16.5 13.0 17.7 16.5 16.6 15.2 1.88 12.3
SD 1.54 2.02 1.91 2.19 1.89 3.17 1.88 2.22
%CV 9.9 15.2 14.7 13.3 14.5 18.0 11.4 13.4 13.8
Derivative
(DF/sec)
Mean 0.019 0.018 0.019 0.020 0.017 0.020 0.020 0.020 0.019 0.001 5.5
SD 0.003 0.003 0.002 0.003 0.003 0.004 0.004 0.003
%CV 17.0 16.9 12.8 16.4 15.0 17.8 18.6 14.8 16.1
Integral
(DF/F x sec)
Mean 3.33 3.27 3.31 4.04 3.46 3.59 3.51 3.74 3.53 0.261 7.4
SD 0.41 0.41 0.43 0.43 0.53 0.59 0.49 0.55
%CV 12.2 12.4 13.1 10.7 15.3 16.5 14.0 14.6 13.6
Noise (DF/F) Mean 0.007 0.006 0.006 0.006 0.004 0.008 0.006 0.007 0.006 0.001
SD 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001
Eight control plates were subjected to a stimulus protocol comprised of 1) a 5 Hz, 30 sec, 2) a 10 Hz, 30 sec, and 3) a 50 Hz, 15 sec pulse train in succession, with a 5
minute inter-train interval. Amplitude, decay time constant, peak first derivative, response integral, and baseline noise for the response to the 10 Hz train are shown.
doi:10.1371/journal.pone.0025999.t001
Figure 4. MANTRA system responses depend on action potential-mediated opening of presynaptic Ca
++ channels. (A) TTX
concentration-response curve for response amplitudes to a 30 Hz, 10 sec pulse train from a single plate. Each point shows the mean 6 SEM of 8 wells
normalized to within-plate vehicle controls. Data were fit with a standard sigmoid concentration-response function (R
2=0.99). (B) SypHy fluorescence
responses during a 30 Hz, 10 second stimulus train in the presence of the Cav2.1 inhibitor v-agatoxin IVA (500 nM), the Cav2.2 inhibitor v-conotoxin
GVIA (1 mM), and the Cav2.3 inhibitor SNX-482 (1.2 mM). The waveforms depicted are an average of 24 wells for the vehicle and 8 wells for the
treatment group. (C,D) Amplitudes (mean 6 SEM) of the sypHy responses shown in (B) following (C) 30 pulses (1 sec) and (D) 300 pulses (10 sec) of
the stimulus train (***: p,0.0001).
doi:10.1371/journal.pone.0025999.g004
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that increased the 30 Hz/5 Hz amplitude ratio, and 11 of these
hits are known adenosine A1 agonists (Figure 6B; see Dataset S2
for complete dataset). In all cases, the increase in this ratio resulted
from a decrease in the amplitude of the response to the 5 Hz train
and not from an increase in the 30 Hz response amplitude (Figure
S3). Adenosine A1 receptors have long been known to be
presynaptic receptors whose activation results in reduced synaptic
vesicle release [37,38]. Our screening results suggest that high
frequency stimulation can overcome this inhibitory mechanism
and demonstrate the capacity of the MANTRA system to rapidly
identify novel mechanistic aspects of synaptic vesicle cycling.
Discussion
In this report, we describe the development and validation of the
MANTRA system: a high throughput technology capable of
performing kinetic assays of the synaptic vesicle cycle directly in
primary neurons. We demonstrate that this system operates with high
precision, uniformity, sensitivity, and reproducibility and is capable of
detecting modulators of synaptic vesicle cycling in a high-throughput
screening mode. When using a complex stimulation protocol
covering a broad range of synaptic activity regimes, at least 1,500
wells, or 500 agents when screened in triplicate, can be analyzed on
the MANTRA system per day. With this throughput, the system can
be used to screen for modulators of presynaptic function.
Two key technological advances were necessary for the
development of the MANTRA system: 1) a primary neuronal
culture and synaptic vesicle cycling reporter system that generates
strong signals with a high signal-to-background ratio, and 2) novel
instrumentation integrating a sensitive, parallel-imaging compo-
nent and a 96-electrode stimulation system. While other screening
instruments with integrated imaging and field stimulation
components have been described, they are limited to measuring
eight wells in parallel [39,40]. Since those systems were developed
for ion channel assays, which are typically of short duration, this
limitation has a relatively minor impact on assay throughput in
that context. However, for analysis of the synaptic vesicle cycle,
assay durations of tens of minutes are required to cover a broad
range of stimulation parameters. Therefore, the throughput of the
previously described instruments [39,40] is insufficient for high-
throughput screening of presynaptic function.
Potential impact of the MANTRA system
The MANTRA system enables unbiased functional high
throughput screening of presynaptic activity directly in primary
neurons using physiologically relevant patterns of stimulation. This
application has the potential to significantly expand our under-
standing of presynaptic function. As described in this report, the
MANTRA system can be used for screening libraries of chemical
agents with known pharmacological activities to elucidate
presynaptic molecular mechanisms. By employing this approach
and screening two compound plates, we were able to rapidly
identify a novel property of adenosine A1 receptor-mediated
modulation of presynaptic function. Moreover, through the
screening of RNAi libraries, the MANTRA system has the
Figure 5. The MANTRA system can detect modulators of synaptic vesicle cycling. (A) SypHy traces from neuronal cultures treated with
PMA (1 mM) or vehicle (0.7% DMSO) generated with the high resolution microscope system (HiRes) or the MANTRA system in response to a 5 Hz,
30 sec stimulus train. Scale bar: 0.1 DF/F, 20 sec. (B) Vehicle-normalized amplitudes (mean 6 SEM) in response to the 5 Hz, 30 sec stimulus train in
vehicle- and PMA-treated cultures measured on the microscope based system (HiRes; n=3) and on the MANTRA system, for which statistics were
generated from three randomly selected PMA- and vehicle-treated replicates. (C) The plate of the LOPAC library containing PMA was screened in
triplicate on the MANTRA system (10 mM; 1 hour incubation) using a stimulation protocol consisting of a 5 Hz, 30 sec train, a 10 Hz, 30 sec train, and
a 30 Hz, 15 sec train with stimulation trains separated by 5 minute intervals. Shown are the amplitudes (mean 6 SEM) of the three replicates for each
compound normalized to the mean amplitude of the vehicle wells. Dotted lines indicate three standard deviations from the vehicle mean. Red points
indicate vehicle wells, blue point indicates PMA. Green point indicates N6-phenyladenosine as further described in Figure 6. (D) PMA concentration-
response curve for response amplitudes to the 5 Hz train generated from a single plate. Each point shows the mean 6 SEM of 8 wells normalized to
within-plate vehicle controls. Data were fit with a standard sigmoid concentration-response function (R
2=0.95).
doi:10.1371/journal.pone.0025999.g005
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involved in the regulation of neurotransmitter release.
The MANTRA system has major applications for the discovery
of novel mechanism-based therapies for multiple central nervous
system (CNS) disorders, many of which represent largely unmet
medical needs. Alterations in presynaptic function have been
implicated in schizophrenia [5,6], depression [7], epilepsy [8],
autism [9], attention deficit/hyperactivity disorder [10], Alzhei-
mer’s disease [11], Parkinson’s disease [12], Huntington’s disease
[13], and migraine [14]. While significant progress has been made
towards identifying the genetic and molecular alterations present
in CNS disorders, it has been challenging to translate this body of
knowledge into the identification of single, attractive drug targets
that are amenable to traditional drug discovery efforts [41].
Rather, we propose that innovative, functional screening ap-
proaches are needed to address disease mechanisms for complex,
multi-factorial psychiatric and neurological disorders. In this
regard, the application of the MANTRA system to cellular models
of CNS diseases may lead to the discovery of novel compounds or
targets that restore aberrant synaptic function and serve as the
basis for new mechanism-based treatments.
The repertoire of genetically encoded optical reporters for
multiple neuronal processes is rapidly expanding [42]. Such
reporters can be targeted to specific subcellular compartments by
fusing them to proteins with appropriate targeting sequences
[43,44] and can be expressed in defined neuronal subtypes via cell-
subtype specific promoters [45]. With the incorporation of such
reporter systems, the applications of the MANTRA system can be
expanded to address multiple aspects of neuronal function in
different subcellular compartments of disease-relevant neuronal
subtypes. With its unique and broad capacity for unbiased, high-
throughput screening of synaptic function, we believe that the
MANTRA system has the potential for major impact on basic
neuroscience research and on CNS drug discovery.
Materials and Methods
Cell Culture
All experimental procedures were performed in accordance
with the NIH Guide for the Care and Use of Laboratory Animals.
In addition, all experimental procedures and protocols were
reviewed and approved for use by the Galenea IACUC
Committee. E18 embryos were recovered by postmortem
caesarian section from euthanized pregnant Sprague-Dawley rats.
Embryo forebrains were dissected, digested in HBSS (Invitrogen)
containing 0.25% trypsin and 0.1% DNAse, and dissociated by
trituration through fire-polished Pasteur pipettes. Neurons were
plated and maintained in Neurobasal Medium (Invitrogen) plus
2% B-27 Supplement (Invitrogen), 500 mM glutamine (Invitro-
gen), and 6.25 mM glutamate (Sigma) and were incubated at 37uC
in a 95% air/5% CO2 humidified incubator for 19–23 days before
use. For high resolution assay experiments, neurons were plated
onto poly-D-lysine (BD Biosciences) and laminin (BD Biosciences)
coated 25-mm square coverslips (Carolina Biological Supply)
inside a 5-mm-diameter cloning cylinder at 20,000 cells/cylinder.
For the high-throughput assays, neurons were plated into poly-D-
lysine coated, black-walled, thin-bottomed 96-well plates (Greiner
Biosciences) at 75,000 cells/well in 150 ml/well of medium.
Figure 6. High frequency stimulation overcomes adenosine A1 agonist-induced suppression of synaptic vesicle release. (A) The ratio
of the amplitudes of the responses to the 30 Hz train to amplitudes of the responses to the 5 Hz train was determined for the compounds from the
LOPAC plate described in Figure 5C. The depicted data (mean 6 SEM) were normalized to the mean of the vehicle control wells. Dashed line indicates
three standard deviations from the mean of the vehicles. Red points indicate vehicle wells. Blue point indicates PMA. Green point indicates N6-
phenyladenosine. Inset shows the average waveforms from the three replicates of N6-phenyladenosine and the 36 vehicle replicates from the three
replicate screening plates. Red bars indicate periods of stimulation Scale bar: 0.05 DF/F, 20 sec. (B) A single plate of compounds targeting adenosine
and purine receptors (Enzo Life Sciences) was screened as described in Figure 5C. Data are as described in (A). Green circles indicate compounds that
generated effects greater than three standard deviations from the mean of the vehicles.
doi:10.1371/journal.pone.0025999.g006
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The synaptophysin-pHluorin reporter [21] and the human
synapsin promoter [23] sequences were as previously described.
The expression construct was generated by custom cDNA
synthesis (Blue Heron Bio). A recombinant adeno-associated virus
of mixed serotype 1/2 (AAV1/2) was generated (GeneDetect).
Titers of the viral preparations were .1X10
12 GP/ml. At 7 DIV,
neurons were infected with the hSyn-SypHy-AAV at 2500 MOI.
Immunocytochemistry
Primary rat neuronal cultures on coverslips were infected with
the hSyn-SypHy-AAV at 7 DIV. At 21 DIV, neurons were fixed in
4% formaldehyde, permeabilized in 0.3% Triton X-100, and
blocked in 0.1% Triton X-100 plus 10% normal goat serum
(Sigma). Neurons were incubated with primary antibodies, mouse
anti-synaptotagmin (1:1000; Synaptic Systems) and rabbit anti-
GFP (1:1000; Abcam), overnight at 4uC, rinsed in PBS, and
incubated in secondary antibodies, Alexa-Fluor488 conjugated
goat anti-rabbit IgG (1:1000; Invitrogen) and Alexa-Fluor555
conjugated goat anti-mouse IgG (1:1000; Invitrogen). Neurons
were rinsed, mounted onto glass slides using Fluoromount G
(Southern Biotech), and visualized with a Zeiss Axiovert Z1
microscope using a 40X 1.3NA oil immersion objective lens.
Colocalization analysis was performed using ImageJ.
High-resolution sypHy assays
Coverslips bearing neuronal cultures were washed in assay
buffer which contained (in mM): NaCl 119, KCl 2.5, dextrose 30,
HEPES 25, MgCl2 2, CaCl2 2, D-(2)-2-amino-5-phosphonopen-
tanoic acid (D-AP5) 0.05, and 6,7-dinitroquinoxaline-2,3-dione
(DNQX) 0.02. Coverslips were mounted in a custom-built
perfusion and stimulation chamber secured to the stage of a Zeiss
Axio Observer A1 microscope. Cultures were perfused at a rate of
100 ml/min using multiple peristaltic pumps, each connected to a
different input reservoir. Pharmacological agents were introduced
by switching peristaltic pumps. An objective warmer (Bioptechs)
was used to maintain bath temperature at 30uC. To elicit action
potentials, 1 ms voltage pulses (10 V) were passed between two
5 mm platinum sheet electrodes positioned on either side of the
recording chamber. Stimulus patterns were delivered by a stimulus
isolation unit (Coulbourn Instruments) controlled by Igor Pro
software (Wavemetrics) and a DAQ system (National Instruments).
Cultures were illuminated by a 475 nm LED (Cairn) and
fluorescence was filtered with a 470/525 emission/excitation filter
cube (Zeiss). Cultures were imaged with a 1.3 NA 40x oil-
immersion objective lens, and fluorescence images were acquired
with an iXON electron multiplying CCD (EMCCD) camera
(Andor) with 50 msec exposures at a frequency of 1 Hz. Mean
whole-field fluorescence intensity for each image was extracted
using ImageJ. Resulting time-varying fluorescence waveforms
were analyzed with custom routines (Igor Pro).
MANTRA system assays
96-well plates containing neuronal cultures at 21–23 DIV were
placed on the platform of an Evolution P3 liquid handling robot
(EP3; Perkin Elmer) with which culture medium was replaced with
assay buffer. Plates were transferred to a 30uC incubator for one
hour, transferred to the plate tray in the MANTRA instrument,
and subjected to a read/field stimulation protocol. Fluorescence
readings were made using a 475/535 nm excitation/emission
filter. Unless specified otherwise, field stimulus pulses were 30 V,
0.2 msec. This stimulation intensity was chosen for its ability to
reliably initiate action potentials in all neurons in all wells. SypHy
responses to these stimuli were completely abolished by TTX,
demonstrating that these responses are action potential-mediated
(see Figure 4A). The temperature of the cabinet was set at 32uC,
resulting in an assay buffer temperature of 30.5 to 31.5uC. Wells
were imaged at 1 Hz with 100 msec exposures. Data files were
post-processed using in-house analysis routines (Igor Pro) and
stored in a custom MySQL database. As a result of sporadic
inconsistencies in assay buffer aspiration into the central capillary
of the electrodes, stimulation failures can occasionally occur.
Failures were specified as any wells in which the DF/F in response
to a 50 Hz, 15 sec or a 30 Hz, 10 sec stimulation train was less
than 0.05. Typically 0–3 wells were removed from analyses from
each 96-well plate as a result of stimulation failures.
For compound screening, a 1.5 mM dilution plate was
generated using an EP3 liquid handling robot (Perkin Elmer).
2 ml of compounds were transferred from this dilution plate to
each of three near assay-ready compound plates in pseudo-
randomized locations using a Janus liquid handling station (Perkin
Elmer). Assays were performed as described above. Compounds,
including TTX (Tocris) and the Ca
++ channel inhibitors v-
agatoxin IVA, v-contoxin GVIA, and SNX-482 (Alomone Labs),
were added with the final buffer addition of the plate wash process.
Supporting Information
Figure S1 MANTRA system temperature control system
validation. Well temperature was measured using a thermocouple
inserted into well H1 of a 96-well plate during an electrostimu-
lation protocol. Temperature of the metal plate tray, monitored by
an independent thermocouple inserted into the tray, remained
constant at 32uC throughout the run. The plate was preincubated
at 31uC and placed on the plate tray in the instrument. The plate
lid was removed and temperature logging was started at t=0.
Removal of the lid caused the temperature to drop due to
evaporation. Within one minute the tip module entered the plate
wells. The presence of the tip module reduced evaporation causing
the temperature to re-equilibrate to approximately 31uC. When
the tip module was removed at the end of the run a temperature
decrease was again observed. Well temperature remained within
0.5uC of the target temperature of 31uC throughout the 35 minute
stimulation protocol.
(TIF)
Figure S2 Confirmation of hits from the LOPAC library plate
on the MANTRA system. Three assay plates were run on the
MANTRA instrument each containing six replicates (10 mM) of
each of the twelve hit compounds from LOPAC plate 13 (n=18;
see Figure 5C). Shown are the amplitudes of the responses to 5 Hz
stimulation (mean 6 SEM) normalized to the mean amplitude of
the eight vehicle wells on the same plate. Each compound altered
the response amplitude in the direction observed on the initial
screening plates (t-test; ** p,0.001; *** p,0.00001).
(TIF)
Figure S3 Response amplitudes for compounds in a plate of
adenosine/purinergic-focused compounds. A plate containing
compounds targeting purine and adenosine receptors (Biomol)
was screened as described in Figure 6. Shown are the amplitudes
of the responses to the 5 Hz (A) and 30 Hz (B) trains normalized
to the vehicle controls. Dotted lines indicate three standard
deviations from the mean of vehicle wells. Green circles indicate
hit compounds that increases the 30 Hz:5 Hz response amplitude
ratio (see Figure 6).
(TIF)
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30 sec trains. See Table 1 for explanation. Baseline noise is as in
Table 1.
(DOC)
Table S2 Summary statistics from 8 control plates for 50 Hz,
15 sec trains. See Table 1 for explanation. Baseline noise is as in
Table 1.
(DOC)
Dataset S1 MANTRA system screening data for a single
LOPAC plate.
(XLS)
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